Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
Vallon Pharmaceuticals Inc. (NASDAQ: VLON) will host a live video webcast featuring David Baker, President and CEO, on May 18, 2021, at 4:15 PM ET. The event is part of the Q2 Virtual Investor Summit, where management will also engage in one-on-one meetings with registered investors. The presentation will be accessible via the Company’s website and archived for 90 days. Vallon focuses on developing innovative treatments for CNS disorders, including its investigational product candidate, ADAIR, for ADHD and narcolepsy.
- None.
- None.
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET
PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the Q2 Virtual Investor Summit on Tuesday, May 18th at 4:15 PM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A live video webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (www.vallon-pharma.com) and will be archived for 90 days following the event.
About Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
For more information about the company, please visit www.vallon-pharma.com.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com
FAQ
When is Vallon Pharmaceuticals' live video webcast event?
Who will present at the Q2 Virtual Investor Summit for VLON?
What is the focus of Vallon Pharmaceuticals?
What is ADAIR, the investigational product of Vallon Pharmaceuticals?
Where can I watch the Vallon Pharmaceuticals presentation after the event?
